Access Menu

Log in via Social

Rani Therapeutics

Rani Therapeutics

Transforming drug delivery by turning injectables into pills tackling $170B market

This company and others may be fundraising.

Login or signup to access deals.

Company Overview

Turning Injectables Into Pills:

Rani is developing a novel approach for the oral delivery of biologics, a $170BN market of injectable drugs used to treat chronic diseases such as diabetes and rheumatoid arthritis. We've successfully delivered 2 commercially available drugs in pre-clinical trials with 100% equivalence to injection.

Traction

  • Seasoned team with 15 exits: $380M invested and $1.8B returned to investors

    June, 2015
  • Over 50 patents filed in US and abroad with 11 patents issued

    June, 2015
  • Successfully delivered 2 commercially available drugs in preclinical trials with 100% equivalence to injections

    June, 2015
  • $20M invested by Novartis, Google Ventures, Stevanato Group, InCube Ventures and VentureHealth

    June, 2015
  • Unprecedented pre-clinical results

    June, 2015
  • Closed first option/license deal

    June, 2015

Testimonials

Blake Byers
Blake Byers
General Partner at Google Ventures
"Today we are in an age where advances in life sciences are increasing at an unprecedented rate. We are excited by the team's strong track record in pre-clinical studies and look forward to the day Rani will improve the lives of patients."
Novartis
Novartis
To Pharmatechnologist.com
"To date, all attempts to convert biologics to pills have failed. Novartis in collaboration with Rani Therapeutics will most likely be the first company to provide oral delivery of biologics to patients."
Loading...

You Might Be Interested In

Kentucky Dairy Product Innovations, LLC
Kentucky Dairy Product Innovations, LLC
Lactose Free AND Low Calorie Milk Patent Pending - $1 billion market
$115,000 of $1,000,000
12% of goal
Excellent ROI with strong margins of 45%
View Company
Funded
Joey New York/OTC: JOEY
Joey New York/OTC: JOEY
Evolution takes time, but beauty doesn't have to.
$1,230,000 of $4,000,000
100% of goal
Transparency and liquididity of a publicly traded company
View Company
GluCase
GluCase
Live life untethered with the world's first smartphone case glucometer!
$2,813,502 of $750,000
375% of goal
Commercialization partnership with OtterBox: #1 smartphone case
View Company
SPORTHO HOLDING, LLC
SPORTHO HOLDING, LLC
International Expansion of Sportho all-rounds sports medical care centers with state-of-the-science medical care.
$51,400 of $500,000
10% of goal
Sports and care centralized
View Company